Drugs / JNJ 40929837
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01241422 | Nov 2010 → Jun 2011 | asthma | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-40929837 | “JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 production.” PMID 25018015 ↗ Jul 2014 |
| Action | Inhibit | “JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 production.” PMID 25018015 ↗ Jul 2014 |
| Route | Oral | “JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 production.” PMID 25018015 ↗ Jul 2014 |